MARKET

GNCA

GNCA

Genocea Biosciences Inc
OTCPK

Real-time Quotes | Nasdaq Last Sale

0.017
-0.001
-2.94%
Opening 09:30 07/01 EDT
OPEN
0.017
PREV CLOSE
0.017
HIGH
0.017
LOW
0.017
VOLUME
2.77K
TURNOVER
46
52 WEEK HIGH
2.680
52 WEEK LOW
0.012
MARKET CAP
969.93K
P/E (TTM)
-0.0312
1D
5D
1M
3M
1Y
5Y
The Week Ahead In Biotech (June 5-11): Adcom Test For Novavax, ASCO Presentations, Enzo Biochem Earnings And More
Biotech stocks reversed course along with the broader market and closed the week ending June 3 lower. The sector's lean run thus got extended.
Benzinga · 06/05 20:09
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 36 companies achieved new lows for the year.
Benzinga · 05/31 16:06
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Benzinga · 05/31 12:19
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Investor Place · 05/31 11:23
The Week Ahead In Biotech (May 30-June 4): FDA Decision For Eton's Partnered Epilepsy Drug, ASCO Conference Gets Underway And More
Biotech stocks advanced in the week ended May 27, tracking the overall positive sentiment of the broader market. Notwithstanding the week's strength, the sector has been one of the worst performers for the year-to-date period.
Benzinga · 05/30 18:03
20 Stocks Moving in Thursday's Pre-Market Session
Gainers TC Biopharm (Holdings) Plc (NASDAQ: TCBP) shares rose 51.2% to $0.9603 in pre-market trading after dipping 18% on Wednesday.
Benzinga · 05/26 10:46
GRPN, GNCA and LAB among mid-day movers
=Gainers: BlackSky Technology (BKSY) +93%. StoneMor (STON) +51%. Genocea Biosciences (GNCA) +35%. Hoegh LNG Partners (HMLP) +31%. Caleres (CAL) +27%. Evelo Biosciences (EVLO) +20%. Spire Global (SPIR) +17%. Groupon (GRPN)
Seekingalpha · 05/25 16:49
HAPP Stock Soars 38% as Happiness Development Embraces EVs
Investor Place · 05/25 15:03
More
No Data
Learn about the latest financial forecast of GNCA. Analyze the recent business situations of Genocea Biosciences Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
33.33%Buy
66.67%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average GNCA stock price target is 3.080 with a high estimate of 6.00 and a low estimate of 0.1600.
High6.00
Average3.080
Low0.1600
Current 0.0165
EPS
Actual
Estimate
-0.18-0.13-0.09-0.04
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 60
Institutional Holdings: 34.61M
% Owned: 58.88%
Shares Outstanding: 58.78M
TypeInstitutionsShares
Increased
11
216.67K
New
3
20.47K
Decreased
7
116.75K
Sold Out
4
41.37K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.03%
Pharmaceuticals & Medical Research
-0.06%
Key Executives
Non-Executive Chairman/Independent Director
Kenneth Bate
President/Chief Executive Officer/Director
William Clark
Chief Financial Officer
Diantha Duvall
Executive Vice President
Raymond Stapleton
Chief Scientific Officer
Jessica Flechtner
Other
Girish Aakalu
Independent Director
Katrine Bosley
Independent Director
Jennifer Herron
Independent Director
Michael Higgins
Independent Director
John Lunger
Independent Director
George Siber
No Data
No Data
About GNCA
Genocea Biosciences, Inc. is a biopharmaceutical company that is engaged in discovering and developing cancer immunotherapies using its Antigen Lead Acquisition System (ATLAS) technology platform. The Company’s Antigen Lead Acquisition System (ATLAS) technology platform allows to identify targets based on each person’s tumor antigen-specific T cell responses. Its programs include GEN-009 is a neoantigen vaccine candidate delivering adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. Its GEN-011 program is an adoptive T cell therapy using neoantigen-targeted peripheral T cells (NPTs). The GEN-011 NPTs is preferred for ATLAS-identified anti-tumor antigens that are used to manufacture a peripheral blood-derived, tumor-specific T cell therapy.

Webull offers kinds of Genocea Biosciences Inc stock information, including OTCPK:GNCA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GNCA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GNCA stock methods without spending real money on the virtual paper trading platform.